Close

Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

By 2033, World Market For APIs Could Reach US$ 384 Billion

The worldwide active pharmaceutical ingredient market size happened to...

Market Forecast For Innovative Small Molecule Injectables

A Business Research Company report goes on to predict...

Forecast: Bioinformatics Industry Will Reach $31.71B By 2031

As per new market research that’s titled 'Bioinformatics Market...

Merck known as MSD outside the United States and Canada, announced that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, will present an overview of the company’s oncology program at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 6, 2016 at 5:45 p.m. CDT (6:45 p.m. EDT).

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx or by dialing (866) 486-2604 and using ID code number 21794108.

About Merck
For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn. You can also follow our Twitter conversation at $MRK.

Contact: Merck Media:
Lainie Keller, (908) 236-5036
or


Investor:
Teri Loxam, (908) 740-1986
or
Justin Holko, (908) 740-1879

Latest stories